Weekly Digest - August 2025
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - August 2025
27 July 2025: Chong Kun Dang’s ADC-based anticancer drug receives FDA approval for Phase 1/2 clinical trials
- Chong Kun Dang secures FDA nod to launch U.S. Phase 1/2 trials for CKD-703, an ADC therapy targeting NSCLC and solid tumors
- CKD-703 uses next-generation ADC technology fused with the company’s proprietary monoclonal antibody targeting c-Met, aiming to selectively deliver cytotoxic drugs to cancer cells while minimizing systemic toxicity
- Chong Kun Dang advances global ADC ambitions with CKD-703, its first antibody-drug conjugate, developed using proprietary and international technologies and backed by Korea’s national drug development fund
